Evidence map›Paper›PMID 38938812›Full record

ArticleJACS Au2024

Structure-Based High-Efficiency Homogeneous Antibody Platform by Endoglycosidase Sz Provides Insights into Its Transglycosylation Mechanism.

Yin-Cheng Hsieh, Hong-Hsiang Guan, Chien-Chih Lin, Teng-Yi Huang, Phimonphan Chuankhayan, Nai-Chi Chen, Nan-Hsuan Wang, Pu-Ling Hu, Yi-Chien Tsai, Yen-Chieh Huang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACS Au, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Crystal structure of endo-β-N-acetylglucosaminidase HSα.Acta crystallographica. Section F, Structural biology communications · 2026
    Article
  2. Glycan Remodeling Technologies for Enhancing Antibody Function.Advances in experimental medicine and biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yin-Cheng HsiehOBI Pharma, Inc., No. 508, Sec. 7, ZhongXiao E. Rd, Nangang Dist., Taipei City 115, Taiwan.
Hong-Hsiang GuanLife Science Group, Scientific Research Division, National Synchrotron Radiation Research Center, 101, Hsin-Ann Road, Hsinchu 300092, Taiwan.
Chien-Chih LinLife Science Group, Scientific Research Division, National Synchrotron Radiation Research Center, 101, Hsin-Ann Road, Hsinchu 300092, Taiwan.
Teng-Yi HuangOBI Pharma, Inc., No. 508, Sec. 7, ZhongXiao E. Rd, Nangang Dist., Taipei City 115, Taiwan.
Phimonphan ChuankhayanLife Science Group, Scientific Research Division, National Synchrotron Radiation Research Center, 101, Hsin-Ann Road, Hsinchu 300092, Taiwan.
Nai-Chi ChenLife Science Group, Scientific Research Division, National Synchrotron Radiation Research Center, 101, Hsin-Ann Road, Hsinchu 300092, Taiwan.
Nan-Hsuan WangOBI Pharma, Inc., No. 508, Sec. 7, ZhongXiao E. Rd, Nangang Dist., Taipei City 115, Taiwan.
Pu-Ling HuOBI Pharma, Inc., No. 508, Sec. 7, ZhongXiao E. Rd, Nangang Dist., Taipei City 115, Taiwan.
Yi-Chien TsaiOBI Pharma, Inc., No. 508, Sec. 7, ZhongXiao E. Rd, Nangang Dist., Taipei City 115, Taiwan.
Yen-Chieh HuangLife Science Group, Scientific Research Division, National Synchrotron Radiation Research Center, 101, Hsin-Ann Road, Hsinchu 300092, Taiwan.
Masato YoshimuraLife Science Group, Scientific Research Division, National Synchrotron Radiation Research Center, 101, Hsin-Ann Road, Hsinchu 300092, Taiwan.
Pei-Ju LinLife Science Group, Scientific Research Division, National Synchrotron Radiation Research Center, 101, Hsin-Ann Road, Hsinchu 300092, Taiwan.
Yih-Huang HsiehOBI Pharma, Inc., No. 508, Sec. 7, ZhongXiao E. Rd, Nangang Dist., Taipei City 115, Taiwan.
Chun-Jung ChenLife Science Group, Scientific Research Division, National Synchrotron Radiation Research Center, 101, Hsin-Ann Road, Hsinchu 300092, Taiwan.ORCID https://orcid.org/0000-0002-5157-4288

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) have gradually dominated the drug markets for various diseases. Improvement of the therapeutic activities of mAbs has become a critical issue in the pharmaceutical industry. A novel endo-β-

Identifiers

PMID38938812
PMCPMC11200250

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.